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Background/aim: The purpose of this study was to compare efficacy and safety of a combination chemotherapy regimen consisting
of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) and gemcitabine-cisplatin as first-line therapy in patients with
pancreatic cancer.
Materials and methods: Pancreaticobiliary cancer patients who had Eastern Cooperative Oncology Group performance status score of
0 or 1 (on a scale of 0 to 5, with higher scores indicating greater severity of illness) were evaluated to receive folfirinox or gemcitabine
plus cisplatin. The primary endpoints were progression-free and overall survival time. Safety analysis was also evaluated as secondary
measures.
Results: There were 32 patients in the folfirinox group and 36 patients in the gemcitabine-cisplatin group. The median overall survival
was 18.1 months (7.5–28.7) in the folfirinox group as compared with 9.7 months (6.5–13) in the gemcitabine-cisplatin group (p =
0.009). Median progression-free survival was 16.2 months (9–23.4) in the folfirinox group and 6.9 months (6.1–7.6) in the gemcitabinecisplatin group (p = 0.001).
Conclusion: Folfirinox is an option for the first-line treatment of patients with pancreatic cancer and good performance status.
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1. Introduction
Pancreatic cancer (PC) is one of the leading causes of
cancer mortality in the world. Although new therapeutic
strategies have been developed; unfortunately, the overall
5-year survival is approximate %5 [1] and the fourth
leading cause of deaths caused by cancer in the world
[2]. Several treatment modalities including surgery,
chemotherapy, and molecular and biological targeted
therapy are used for the treatment of pancreatic cancer [3].
Among these modalities, chemotherapy is the treatment
option for treating advanced or metastatic PC [4]. Without
chemotherapy, life span of patients is reported to be only
2–4 months [5].
A single-agent or certain combination chemotherapy
regimens have been shown to prolong survival with
tolerable toxicity profiles. Single-agent gemcitabine has
been used for local, advanced, and metastatic PC. It has
good tolerability and clinical response rate [6,7]. However,

despite this potential, PC still had a poor prognosis;
thus, new chemotherapy regimens have emerged. Since
2011, folfirinox (oxaliplatin, irinotecan, leucovorin, and
fluorouracil combination) regimen has been increasingly
used and becoming gold standard in the treatment of
pancreatic cancer. In several studies, the overall survivals
have ranged from 10 to 32.7 months and progression-free
survivals have ranged from 3 to 20 months [8]. On the
other hand, side effects including neutropenia, diarrhea,
neuropathy, and thrombocytopenia have been seen more
often than isolated gemcitabine regimen
Gemcitabine-based regimen is one of the options for
treatment of unresectable and metastatic pancreatic cancer.
The efficacy and toxicity of this regimen have been studied
in several studies. In one of these studies, gemcitabinecisplatin (Gem-Cis) regimen has better survival results
with respect to other gemcitabine combination; however,
these results are not statistically meaningful [9]. In terms
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of toxicity, Gem-Cis combination had unfavorable results
[10]; however, in these studies, Gem-Cis combination was
not compared to folfirinox in terms of efficacy and safety
directly.
In this study, we retrospectively evaluated the safety
and efficacy of folfirinox and Gem-Cis combination in
unresectable and metastatic pancreatic cancer patients.
2. Materials and methods
Pancreaticobiliary cancer patients who were diagnosed
and treated in Gazi University Oncology Department
between January 2010 and July 2017 were retrospectively
evaluated. Patients’ medical records were investigated
and those who were given either only folfirinox or only
gemcitabine-cisplatin were selected. Patients who did not
come for follow-up, have missing variables, or died before
the first follow-up were excluded. Locally advanced or
metastatic pancreatic cancer was included. Patients who
had Eastern Cooperative Oncology Group performance
status score of 0 or 1 were chosen. The primary end-point
was survival time at the end of the study. Safety analysis
was the secondary end-point. The study was approved by
the local ethic committee (approval number: 2017/147).
Oxaliplatin, 85 mg per square meter of the body-surface
area; irinotecan, 180 mg per square meter; leucovorin, 400
mg per square meter; and fluorouracil, 400 mg per square
meter given as a bolus followed by 2400 mg per square
meter given as a 46-h continuous infusion, every 2 weeks
were given in the folfironox regimen. Gemcitabine at a
dose of 1000 mg per square meter weekly for the 1st and
2nd week, cisplatin at a dose of 100 mg per square meter
weekly for the 1st week, every 3 weeks were given in the
gemcitabine-cisplatin combination regimen
Tumor response was evaluated at every 10–12 weeks
by computed tomography. In some cases, magnetic
resonance imaging (MRI) and positron emission
tomography were also used. Tumor response was assessed
using computed tomography and graded according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.1 [10]. Progression-free survival was defined as
starting from the assignment in a clinical trial to disease
progression or death from any cause. Overall survival is
the duration starting from the time of assignment and
continuing until the date of death due to any cause, or
until the date of censoring at the last time the subject was
known to be alive in intention-to-treat populations.
2.1. Statistical analysis
Patients’ demographic data, tumor stage and
histopathological characteristics, and chemotherapyrelated documented side effects were compared.
Continuous data were presented as mean ± SD.
Categorical variables were provided as percentages. In
univariate analysis, Student’s t-test and Mann–Whitney
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test were used to compare continuous variables while chisquare and Fisher’s exact tests were used for categorical
variables. Kaplan–Meier Survival Analysis was used for
progression-free survival time and overall survival time
estimation. Univariate and multivariate analyses were
performed using Cox proportional hazards regression
to investigate prognostic factors for progression-free
survival (PFS) and overall survival (OS). The variables
which showed potential relation with PFS and OS in the
univariate analyses (p < 0.2) were further evaluated in the
multivariate analyses. A two-sided p-value of 0.05 or less
was considered statistically significant. SPSS 15 was used
for statistical analysis.
3. Results
3.1. Baseline characteristics
Pancreaticobiliary cancer was diagnosed in 169 patients.
Either folfirinox or Gem-Cis therapy was given to 105
patients. A total of 68 patients were eligible for this study,

Table 1. Demographic and disease characteristics of the study
population; ECOG: DM diabetes mellitus, HT: hypertension.
FOLFIRINOX Gem-Cis

p

Patient (n)

32

36

Female (n) (%)

14 (43)

19 (52)

Age (mean)(std)

57.2 ± 5.22

58.3±4.89 0.456

0

11 (34)

13 (36)

0.245

1

21 (67)

23 (64)

0.227

DM (n) (%)

23 (71.9)

25 (69.4)

0.520

HT(n) (%)

28 (87.5)

24 (66.6)

0.140

Smoking (n) (%)

9 (28.1)

14 (38.9)

0.249

Alcohol (n) (%)

2 (6.3)

3 (8.3)

0.557

Adenocancer

30 (93.8)

34 (94.4)

0.258

Signet Ring Cell

0

1 (2.8)

0.789

Anaplastic

0

1 (2.8)

0.789

Neuroendocrine

2 (6.2)

0

0.612

Head

21 (65.6)

20 (55.6)

0.260

Corpus

3 (9.4)

8 (22.2)

0.345

Tail

3 (9.4)

2 (5.6)

0.482

Duodenum-Biliary Tract

5 (15.6)

6 (16.7)

0.812

Stage 2B-3 ( Local Advanced)

12 (37.5)

14 (38.9)

0.553

Stage 4 ( Metastatic)

20 (62.5)

22 (61.1)

0.512

0.309

ECOG (n) (%)

Pathology (n) (%)

Tumour Localization (n) (%)

Stage (n) (%)
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the remaining 37 patients had missing baseline information
or did not attend their first follow-up. Demographic data
and baseline characteristics were shown in Table 1. Thirtytwo patients received folfirinox and 36 patients received
Gem-Cis chemotherapy regimen. The median follow-up
time was 13.6 months for the folfirinox group (min/max
4.4 and 45.3 respectively) and for the Gem-Cis groups it
was 10.9 months (min/max 5.13 and 46.4 respectively).
The number of stage 4 patients was 20 (62.5%) in the
folfirinox group and 22 (61.1%) in the gem-cis group. The
mean folfirinox given was 8.2 cycle (4–17) and the mean
Gem-Cis given was 5.9 (3–14) cycle (p = 0.022). The mean
age in the folfirinox group was 50.2, whereas in the GemCis group it was 58.30 (p = 0.27). ECOG performance
status was also similar in both groups as shown in Table 1.
The major pathologic tumor type in both treatment
groups was adenocarcinoma of the pancreas with 30
(93.8%) patients in the folfirinox group versus 34 (94.4%)
patients for the Gem-Cis group. Tumor localizations were
also similar for both groups, head of the pancreas were
the most frequently seen localization and then corpus and
tale followed as the second and third respectively. Stage 4
patients have outnumbered in treatment arms and liver
was the primary site for metastasis (Table 1).
3.2. Efficacy
Treatment responses and efficacy data were shown
below in Figures 1 and 2. At any time 65.6% of the
folfirinox patients and 86.1% of the Gem-Cis patients had
progression. The median progression-free survival (PFS)
time for the folfirinox patients was 16.2 months (9–23.4)
whereas for the Gem–Cis patients it was 6.9 months

(6.1–7.6) (p = 0.001) (Figure 1) . In subgroup analysis,
the number of patients with metastasis was 20 and their
median PFS was 16.2 months (9.2–23.2). On the other
hand, in the Gem–Cis group there were 22 patients with
metastasis and PFS was 6.4 months (5,4–7.4) (p < 0.05).
The difference was also obvious in the locally advanced
group; for the folfirinox group it was 12 months (3.2–29.3)
while for the Gem-Cis group it was 7.1 months (5.9–8.4)
(p < 0.05).
At the end of the study, in the folfirinox group 12
patients (37.5%) and in the
Gem-Cis group 4 patients (11.1%) were still alive.
The median overall survival (OS) time for the folfirinox
group was 18.1 months (7.5–28.7) and for the Gem–Cis
group it was 9.7 months (6.5–13) (p = 0.009) (Figure 2).
In subgroup analysis for metastatic group, the median OS
in the folfirinox group was 11.3 months ( 5.5–17.4) while
it was 10.3 months ( 5.5–15.1) in the Gem–Cis group (p =
0.34). In the locally advanced group, it was 25.4 months
( 22.7–53) and 7.4 months (6–9.7) for the folfirinox and
Gem–Cis groups respectively (p = 0.005).
3.3. Safety profile
Safety analysis was available for 32 patients in the
folfirinox group and for 36 patients in the Gem-Cis group.
The results are shown in Table 2. Grade 3-4 neutropenia
was more frequently seen in the folfirnox group (56 %vs.
39%, p = 0.224) while grade 3-4 thrombocytopenia was
encountered more often in the Gem-Cis group (9.4% vs.
27.8%, p = 0.016). Anemia frequency in any grade was
similar for both treatment groups. This was also the same
for liver and kidney function test results. The folfirinox

Figure 1. Progression-free survival of the treatment groups.
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Figure 2. Overall survival of the treatment groups.
Table 2. Safety profile of the treatment regimens.
FOLFIRINOX (n:32)

Gem-Cis (n:36)

p

Anemia (n) (%)

24 (75)

30 (83.3)

0.658

Mild

20 (62.5)

26 (72.2)

0.540

Severe

4 (12.5)

4 (11.1)

0.770

Neutropenia (n) (%)

26 (81.25)

26 (72.2)

0.350

Mild

8 (25)

12 (33.3)

0.590

Severe

18 (56.25)

14 (38.9)

0.224

Thrombocytopenia (n) (%)

19 ( 59.4)

17 (47.2)

0.016

Mild

16 (50)

7 (19.1)

0.080

Severe

3 (9.4)

10 (27.8)

0.060

Liver function tests abn. (n) (%)

11 (34.3)

11(30.4)

0.930

Renal funciton tests abn. (n) (%)

12 (37.3)

6 (16.6)

0.090

Diarhea (n) (%)

3 (9.3)

1 (2.7)

0.520

Neuropathy (n) (%)

0

5 (13.8)

-

group had more liver and kidney dysfunction but it was
not statistically significant compared to the Gem-Cis
group.
The number of patients with diarrhea which resulted
in hospitalization was 3 in the folfirinox group, whereas it
was only 1 in the Gem-Cis group (p = 0.52). There were not
any patients having a neurotoxicity in the folfirnox group;
however, in the Gem-Cis group, there were 5 patients who
suffered from severe neuropathic complaints and had
abnormal EMG consistent with neuropathic dysfunction.
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As a result of side effects, the number of patients having
chemotherapy dose reduction was 4 in the folfirinox group
and 5 in the Gem-Cis group. On the other hand, treatment
was terminated in 2 patients in the folfirinox group and in
5 patients in the Gem-Cis group (p > 0.05).
4. Discussion
Prognosis of pancreatic cancer is still far from being
satisfactory, especially for metastatic cases. Several
chemotherapy protocols have been used and gemcitabine-
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based protocols historically have had an important role in
treatment. By combining with other chemotherapeutics, it
was thought that better response rates could be achieved.
However, as this study shows, the folfirinox regimen was
superior to the gemcitabine–cisplatin combination. The
safety analysis of both treatment regimens was similar;
thus, folfirinox must be used as a first-line therapy in the
treatment of pancreaticobiliary cancer.
The gemcitabine–cisplatin combination was previously
compared to isolated gemcitabine treatment in a phase 3
study. In combination regimen, progression-free survival
and the overall response rate was better but overall
survival rate and safety profile were not different between
groups [11]. Contrarily, this combination resulted in
more hematological side effects in another study [12].
In a review comparing gemcitabine-based regimens, in
subgroup analysis, gemcitabine-cisplatin combination had
an advantage for survival but it did not reach statistical
significance [9]. For the tumor response rate, gem-cis
regimen had a better partial and overall response rate.
Moreover, disease progression rate was worse in isolated
gemcitabine group [12–15]. On the other hand, the
folfirinox regimen had a strong impact on overall survival
and progression-free survival compared to isolated
gemcitabine treatment [16–18].
In literature, there are not any studies directly comparing
these two regimens, to our knowledge. Folfirnox protocol
had better survival ratios but also had more side effects
as compared to isolated gemcitabine protocol. In this
study, the folfinox group had more neutropenia, diarrhea
thrombocytopenia, and sensorial neuropathy [18]. In a
metaanalysis comparing all chemotherapy protocols used
in pancreatic cancer were evaluated in terms of toxicity and
efficacy. Although there were not any direct comparison,
folfirinox had the best short- and long-term efficacy
among the 12 chemotherapy regimens. On the other
hand, folfirinox and Gemcitabine + Pemetrexed regimens
had a relatively higher incidence of toxicity than other
regimens [19]. Another metaanalysis comparing toxicity
profiles of these regimens, Gemcitabine + Cisplatin and
folfirinox regimens exhibited the highest incidence rates
of neutropenia [20].
In this study, severe neutropenia and diarrhea were
more frequently seen in the folfirinox group but it did
not reach statistical significance. Contrarily, severe

thrombocytopenia was more prevalent in the gemcitabine
group (p = 0.069). All patients with the diagnosis of
neuropathy belonged to the gemcitabine group. It may be
as a result of the shorter follow-up period for the folfirinox
group and also this should be cautiously interpreted with
the consideration of additive cisplatin toxicity that might
have an impact on these increased side effects.
Survival ratios were consistent with the literature.
In a review, 11 studies were included and the mean
overall survival was 24.2 months (10–32) and the mean
progression-free survival was 15 months ( 3–20)
[8]. Moreover, folfirinox protocol survival ratios were
significantly better than those of the gemcitabine group
in locally advanced patients. However, the difference
diminished in the metastatic group. Increased tumor
burden of the disease that rendered the difference
irrelevant might be the explanation
This study has some limitations. It is retrospective,
single-center, and nonrandomized and this may cause
selection bias and confound. Moreover, safety profiles
data in our analysis may have been missed due to a lack
of identification of adverse events as a result of being
retrospective data. Moreover, our study population was
homogeneous as most patients had good PS, which might
have affected the tolerability of the regimens.
In conclusion, folfirinox is a better option for locally
advanced and metastatic pancreaticobiliary carcinoma
treatment than gemcitabine–cisplatin combination and
can be used as first-line chemotherapy in the real-world
setting. Toxicity profile should be kept in mind, especially
hematological and gastrointestinal toxicity, which can
cause severe morbidity and mortality and be managed by
decreasing or modifying drug dosage.
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